Tracking symptoms in new large B-cell lymphoma patients on chemo
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study checks whether an electronic system that monitors symptoms helps care for people with newly diagnosed large B-cell lymphoma starting R-CHOP or a smaller R-mini-CHOP dose. It mainly looks at capturing events and symptom information rather than changing your cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed large B-cell lymphoma and are starting first treatment with R-CHOP or R-mini-CHOP
- You are 18 years or older
- You can use the internet yourself or have someone at home who can help send symptom reports and complete study forms
- Your general ability to do daily activities is not severely limited (ECOG score is less than 3)
- You can understand the study and agree in writing before any study steps
- You must be enrolled in social security
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study tests a “mini-CHOP-like” chemotherapy plan for newly diagnosed diffuse large B-cell lymphoma (DLBCL) in people age 70 and older. It may help you learn whether this gentler regimen works well and is safe in older adults who are newly starting treatment.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This study uses special lab testing (“omics”) on people with certain fast-growing B-cell lymphomas to find results that can help with diagnosis and predicting outcomes. It may help by improving how clinicians identify the lymphoma type and forecast how it may behave.
This trial tests a new drug (epcoritamab) given with a milder chemotherapy combination (Pola-R-mini-CHP) for people over 70 or who are not healthy enough for standard full-dose chemotherapy. The goal is to see if this approach works as well or better with fewer side effects.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.